33 results
8-K
EX-99.1
RLYB
Rallybio Corp
9 May 24
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
8:11am
Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 ̶
̶ $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March … to progress towards the initiation of our Phase 2 dose confirmation trial for RLYB212 in pregnant women at higher risk of FNAIT, which is on track
8-K
EX-99.1
RLYB
Rallybio Corp
10 Apr 24
Entry into a Material Definitive Agreement
4:10pm
to, statements concerning the timing of initiation of the Phase 2 dose confirmation study for RLYB212, the release of screening numbers of women
8-K
EX-99.1
RLYB
Rallybio Corp
12 Mar 24
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
8:11am
Study for RLYB212 in Pregnant Women at Higher Risk for FNAIT Expected to Initiate in 2H 2024 --
-- $109.9 million Cash, Cash Equivalents … where we will conduct the Phase 2 dose confirmation study for RLYB212 in pregnant women at higher risk for FNAIT. The Phase 2 study remains on track
8-K
EX-99.1
4ue6 6gdd9bg1j7c
6 Feb 24
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
8:15am
8-K
EX-99.1
xkomrcwixw8y cdhs
9 Nov 23
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
8:10am
8-K
EX-99.1
s2znxiasl
8 Aug 23
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
8:16am
424B3
zjxxykq3q
12 May 23
Prospectus supplement
4:50pm
8-K
EX-99.1
uee2cnt127jqyo56pc
9 May 23
Rallybio Reports First Quarter 2023 Financial Results
8:11am
424B5
gd30vq7 0yv
14 Nov 22
Prospectus supplement for primary offering
8:02am
424B5
h1iec0lydprv
10 Nov 22
Prospectus supplement for primary offering
9:23am
8-K
EX-99.1
o2rqnh9 zh
7 Nov 22
Rallybio Reports Third Quarter 2022 Financial Results
8:03am
424B5
1xzb5rih
15 Aug 22
Prospectus supplement for primary offering
5:47pm
S-3
hin8dr8nvgwoew
8 Aug 22
Shelf registration
5:23pm